STOCKHOLM, Sweden--(BUSINESS WIRE)--Medivir AB (STO:MVIRB), Sweden, and Guangdong Lantai Viewland Pharmaceutical, China, announced today the signing of a licensing agreement on MIV-160 (MV026048), a non-nucleoside HIV reverse transcriptase inhibitor (NNRTI) in late pre-clinical development.
